Baldness, benign prostate hyperplasia, prostate cancer and androgen levels

Figures & data

Table I.  Comparison of the findings between prostate cancer and BPH patients.

	BPH	Pca	p
Age	65.37 ± 0.35	67.87 ± 1.23	0.06
PV	61.6 ± 26.6	51.8 ± 24.9	0.039
tPSA	9.0 ± 7.8	28.0 ± 30.1	<0.001
tT	545.3 ± 175.0	524.2 ± 184.8	0.510
fT	6.8 ± 7.8	5.9 ± 4.7	0.498
bT	229.4 ± 58.7	209.0 ± 77.3	0.192
FSH	9.6 ± 7.8	18.3 ± 24.8	0.001
LH	7.0 ± 3.7	11.7 ± 12.1	0.005
Prl	13.7 ± 8.8	13.8 ± 10.3	0.948
E2	27.4 ± 8.1	26.9 ± 9.1	0.646
SHBG	45.65 ± 24.92	39.47 ± 15.20	0.242
Alb	4.21 ± 0.42	4.02 ± 0.48	0.014

Un-paired t-test.

Figure 1. HS of baldness hair patterns as proposed by Norwood and arranged according to no baldness, vertex baldness and frontal baldness.

Table II.  Hair patterning classification among prostate cancer and BPH patients.

	No or little hair loss, n (%)	Vertex baldness, n (%)	Frontal baldness, n (%)
Prostate cancer	6 (14%)	30 (68%)	8 (18%)
BPH	14 (13%)	70 (65%)	24 (22%)

(n = 152) (p = 0.338 Chi-square).

Table III.  Comparison of hormonal levels among BPH and prostate cancer patients and correlation with AA.

	BPH (n = 108)	Prostate cancer (n = 44)	p
Total testosterone (ng/dL)	545.3 ± 17.00	524.2 ± 27.85	0.51
Frontal baldness	510.4 ± 28.16	618.5 ± 45.30	0.071
Vertex baldness	555.4 ± 23.23	519.5 ± 35.78	0.398
No baldness	556.0 ± 39.35	421.9 ± 59.07	0.108
Free testosterone (ng/dL)	6.75 ± 0.76	5.88 ± 0.72	0.498
Frontal baldness	6.04 ± 1.47	4.580 ± 0.763	1.000
Vertex baldness	7.28 ± 1.05	6.452 ± 0.940	0.63
No baldness	5.40 ± 0.73	4.546 ± 2.362	0.331
Bioavailable testosterone(ng/dL)	229.4 ± 8.14	209.0 ± 14.87	0.192
Frontal baldness	289.6 ± 27.31	244.5 ± 18.50	0.606
Vertex baldness	213.8 ± 6.98	207.0 ± 19.66	0.304
No baldness	220.8 ± 12.64	202.6 ± 15.51	0.724
SHBG(nmol/L)	45.65 ± 3.42	39.47 ± 2.92	0.242
Frontal baldness	38.90 ± 4.31	52.00 ± 7.07	0.145
Vertex baldness	47.56 ± 5.20	38.95 ± 3.41	0.304
No baldness	45.10 ± 3.96	36.56 ± 6.09	0.284

Mann–Whitney and un-paired t test.